Rentschler Biopharma appoints Thomas aus dem Siepen as Global Head Digital Manufacturing and Automation

Laupheim (Germany), April 12, 2023 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Thomas aus dem Siepen as Global Head Digital Manufacturing and Automation, effective April 1, 2023. As an experienced leader, he is a member of Rentschler Biopharma's Global Leadership Team and is responsible for the alignment of digitalization and automation – all the way from research and development to production.

Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, said: “I am pleased to warmly welcome Thomas aus dem Siepen to Rentschler Biopharma. He brings strong experience in digital manufacturing. This sub-area of Industry 4.0 aims to digitize and intelligently network production workflows to advance the automation of processes. With his in-depth experience, Thomas aus dem Siepen will make an important contribution to digital excellence at Rentschler Biopharma by connecting the employees of the departments even better with each other. Highly efficient internal planning processes are crucial so that we can focus on our main purpose: to sustainably improve the lives of patients.”

“Rentschler Biopharma is an established partner in the international biopharma landscape. With the requirements of its clients in focus, the family-owned company offers a particularly attractive working environment that is oriented towards the best service and the highest quality standards,” said Thomas aus dem Siepen, Global Head Digital Manufacturing and Automation at Rentschler Biopharma. “I am very much looking forward to the exciting task of making the automation and digital roadmap even more productive and economical, thus contributing to an IT and automation landscape aligned with client expectations and the value chain.”

Before joining Rentschler Biopharma, Thomas aus dem Siepen worked for more than 16 years in various management positions with increasing responsibility at Roche Diagnostics. There, he headed the “MSAT Process Automation” department, which included ownership, control, operation and further development of production-related IT and automation systems for pharmaceutical and clinical production as well as laboratory IT.

Most recently, he established an end-to-end support organization strongly aligned with the Drug Substance core business, the “Manufacturing Value Stream”, which oversaw the entire range of process-relevant configuration of manufacturing processes across all levels of automation and their data use. In addition to the coordination of a large team, his tasks included the creation of strategic roadmaps and the establishment of a global network between the Drug Substance sites for the cooperation and strategic alignment of automation concepts and their standardization. In previous positions, his responsibility was in the field of automation where he led the planning, implementation and support of automation and MES software for pharmaceutical production facilities.

Prior to Roche Diagnostics, Thomas aus dem Siepen worked as an IT consultant and software developer at Sydecon GmbH and Syskoplan AG. He is a biologist with a degree from the Friedrich-Alexander-University of Erlangen, Germany.
 

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.

Contact:

Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: +49-7392-701-874
communications@rentschler-biopharma.com

Media inquiries:

For a high-resolution image, please contact communications@rentschler-biopharma.com.